# OnCo record paper-innovatv-301-tisotumab-nejm-2024 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-innovatv-301-tisotumab-nejm-2024/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-innovatv-301-tisotumab-nejm-2024" ;
  schema:name "innovaTV 301: tisotumab vedotin versus chemotherapy as second- or third-line therapy for recurrent cervical cancer"@en ;
  schema:description "The tissue factor-directed antibody-drug conjugate tisotumab vedotin lengthened survival compared with chemotherapy in cervical cancer that had progressed after first-line treatment, at the cost of eye and nerve side effects."@en ;
  schema:url <https://onco.cc/key-papers/paper-innovatv-301-tisotumab-nejm-2024/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:citation <https://doi.org/10.1056/NEJMoa2313811>, <https://pubmed.ncbi.nlm.nih.gov/38959480/> ;
  schema:sameAs <https://doi.org/10.1056/NEJMoa2313811> ;
  schema:datePublished "2024"^^xsd:gYear ;
  schema:author "Vergote I, González-Martín A, Fujiwara K, et al." ;
  onco:cancers <https://onco.cc/cancers/recurrent-metastatic-cervical-cancer/> ;
  onco:drugs <https://onco.cc/drugs/tisotumab-vedotin/> ;
  onco:trials <https://onco.cc/trials/innovatv-301/> ;
  onco:journals <https://onco.cc/journals/nejm/> .